ArticleNaunyn-Schmiedeberg's archives of pharmacology1995
Caffeine enhances sympathetic purinergic and noradrenergic transmission in the guinea-pig isolated vas deferens.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- Butylidenephthalide facilitates contractions via nonspecific binding to receptors in isolated guinea-pig vas deferens.Pharmaceutical biology · 2019Article
- The sources and sequestration of Ca(2+) contributing to neuroeffector Ca(2+) transients in the mouse vas deferens.The Journal of physiology · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intracellular recording techniques were used to monitor the resting membrane potential of smooth muscle cells and the excitatory junction potentials (EJPs) evoked by stimulation of the hypogastric nerve. Stimulation with trains of 15 pulses at 1 Hz or 0.33 Hz evoked individual EJPs which increased in amplitude from the first pulse and reached a plateau after 6-8 pulses. Stimulation at 1 Hz resulted in EJPs facilitating to a plateau level of approximately 25 mV, whereas with stimulation at 0.33 Hz the EJPs only facilitated to a plateau level of about 12 mV. With stimulation at 1 Hz, caffeine (3 mM and 10 mM), increased the amplitude of the first few EJPs in each train and decreased the extent of facilitation and reduced the amplitude of fully facilitated EJPs. In comparison, the amplitude of all EJPs evoked by stimulation at 0.33 Hz was increased by caffeine (3 mM and 10 mM). With 0.33 Hz stimulation, facilitation of the first few EJPs was observed in the presence of 3 mM caffeine but not in the presence of 10 mM caffeine. In the presence of the alpha 2-adrenoceptor antagonist idazoxan, caffeine (3 mM and 10 mM) still enhanced the amplitude of EJPs early in trains of stimulation but there was no depression of EJPs later in the trains. Similarly, in reserpine-treated vasa deferentia, caffeine (3 mM) enhanced EJPs early in the train of stimulation at 1 Hz and there was no depression of EJPs at the end of the train. In addition to electrophysiological experiments, the effect of caffeine (0.1-30 mM) on the resting and stimulation-induced (S-I) efflux of radioactivity was investigated in guinea-pig isolated vasa deferentia previously incubated with [3H]-noradrenaline. Caffeine (10 mM) did not affect the resting efflux of [3H]-noradrenaline but significantly enhanced the S-I efflux by 150-160%. The present findings suggest that caffeine enhances sympathetic purinergic and noradrenergic transmission at the sympathetic neuroeffector junction in the guinea-pig vas deferens. Moreover, the increased release of transmitter noradrenaline can modulate purinergic transmission by activation of alpha 2-adrenoceptors located at sympathetic neuroeffector sites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.